Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Gallium citrate Ga-67 is a radiopharmaceutical agent used in the detection of the presence and extent of Hodgkin's disease, lymphoma, and bronchogenic carcinoma, as well as some acute inflammatory lesions. Although the mechanism is unknown, gallium Ga 67 concentrates in lysosomes and is bound to a soluble intracellular protein in certain viable primary and metastatic tumors and focal sites of inflammation, allowing scintigraphic localization.
- Mechanism
- Curator reviewed
Gallium Citrate Ga 67, with no carrier added, has been found to concentrate in certain viable primary and metastatic tumors as well as focal sites of infection. The body generally handles Ga3+ as though it were ferric iron (Fe-III), and thus the free isotope ion is bound (and concentrates) in areas of inflammation, such as an infection site, and also areas of rapid cell division. Ga-67 binds to transferrin, leukocyte lactoferrin, bacterial siderophores, inflammatory proteins, and cell-membranes in neutrophils, both living and dead. Lactoferrin is contained within leukocytes. Ga-67 may bind to lactoferrin and be transported to sites of inflammation, or binds to lactoferrin released during bacterial phagocytosis at infection sites (and remains due to binding with macrophage receptors). Ga-67 also attaches to the siderophore molecules of bacteria themselves, and for this reason can be used in leukopenic patients with bacterial infection (here it attaches directly to bacterial proteins, and leukocytes are not needed). Uptake is thought to be associated with a range of tumour properties including transferring receptors, anaerobic tumor metabolism and tumor perfusion and vascular permeability.
- Primary indication
- Gallium Citrate Ga 67 Injection may be useful to demonstrate the presence and extent of Hodgkin's disease, lymphoma, and bronchogenic carcinoma.Curator reviewed · 4 structured indications
- Formula / weight
- C6H5GaO7 · 256.0279 g/mol (avg)
- First approval
- United States, 1976
- Also known as
- Gallium (67 Ga) citrate · Gallium (67ga) citrate · Gallium citrate Ga 67 · Gallium-67 Citrate
- Brand names
- Gallium
Resolves to
YEEGWNXDUZONAA-RYDPDVNUSA-KSMILES[67Ga+3].OC(CC([O-])=O)(CC([O-])=O)C([O-])=OWhat you can answer from here — as of July 03, 2026
Which drugs share a target with Gallium citrate Ga-67, and which of those have an active Phase 3 trial?